Abstract
The aim of this study was to determine the genotypic variation of hepatitis C among drug users in Flanders and to relate the distribution of genotypes to the characteristics of the population. Hepatitis C virus RNA (HCV-RNA) quantification and genotyping was performed on stored samples from 161 anti-HCV-positive injecting and non-injecting drug users. Information on sociodemographic status, drug-related risk behaviour and sexual risk behaviour was available for each drug user. HCV-RNA was present in 152 of 161 samples (94.4%). Genotype 1 was predominant (48.7%), followed by genotype 3 (41.2%), genotype 4 (8.8%) and genotype 2 (1.4%). In the multivariate analysis, lack of a history of injecting drug use was confirmed as a statistically significant predictor for infection with genotype 1. Predictors for infection with genotype 3 were the presence of anti-HBc antibodies and a history of injecting drug use. Being tattooed emerged as a statistically significant predictor for infection with genotype 4. The 94.4% prevalence of HCV-RNA among anti-HCV-positive drug users was considerably higher than the 54–86% chronicity rate found globally among HCV-infected patients. The results of this study suggest the existence of separate transmission networks for injecting drug users and non-injecting drug users. Finally, the results suggest that tattooing practices play a role in the spread of HCV among drug users.
Similar content being viewed by others
References
Anonymous (1997) Hepatitis C: global prevalence. Wkly Epidemiol Rec 72:341–344
Van Damme P, Thyssen A, Van Loock F (2002) Epidemiology of hepatitis C in Belgium: present and future. Acta Gastroenterol Belg 65:78–79
Thomas DL, Cannon RO, Shapiro CN, Hook EW, III, Alter MJ, Quinn TC (1994) Hepatitis C, hepatitis B, and human immunodeficiency virus infections among non-intravenous drug-using patients attending clinics for sexually transmitted diseases. J Infect Dis 169:990–995
Mathei C, Buntinx F, Damme PV (2002) Seroprevalence of hepatitis C markers among intravenous drug users in western European countries: a systematic review. J Viral Hepat 9:157–173
Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander ER (2001) Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health 91:42–46
Crofts N, Jolley D, Kaldor J, Beek I, Wodak A (1997) Epidemiology of hepatitis C virus infection among injecting drug users in Australia. J Epidemiol Community Health 51:692–697
Denis B, Dedobbeleer M, Collet T, Petit J, Jamoulle M, Hayani A, Brenard R (2002) High prevalence of hepatitis C virus infection in Belgian intravenous drug users and potential role of the “cotton-filter” in transmission: the GEMT Study. Acta Gastroenterol Belg 63:147–153
Seeff L (2002) Natural history of chronic hepatitis C. Hepatology 36(Suppl l):S35–S46
Broers B, Junet C, Bourquin M, Deglon JJ, Perrin L, Hirschel B (1998) Prevalence and incidence rate of HIV, hepatitis B and C among drug users on methadone maintenance treatment in Geneva between 1988 and 1995. AIDS 12:2059–2066
Goldberg D, McIntyre PG, Smith R, Appleyard K, Dunlop J, Taylor A, Hutchinson S (2001) Hepatitis C virus among high and low risk pregnant women in Dundee: unlinked anonymous testing. BJOG 108:365–370
Harsch HH, Pankiewicz J, Bloom AS, Rainey C, Cho JK, Sperry L, Stein EA (2000) Hepatitis C virus infection in cocaine users—a silent epidemic. Community Ment Health J 36:225–233
Lamden KH, Kennedy N, Beeching NJ, Lowe D, Morrison CL, Mallinson H, Mutton KJ, Syed Q (1998) Hepatitis B and hepatitis C virus infections: risk factors among drug users in northwest England. J Infect 37:260–269
Orduna A, Bratos MA, Gutierrez P, Almaraz A, Eiros JM, Martin JF, Gonzalez JM, Caro-Paton A, Rodriguez-Torres A (1992) Infection by hepatitis B and C virus in non-intravenous drug using female prostitutes in Spain. Eur J Epidemiol 8:656–659
Page-Shafer KA, Cahoon-Young B, Klausner JD, Morrow S, Molitor F, Ruiz J, McFarland W (2002) Hepatitis C virus infection in young, low-income women: the role of sexually transmitted infection as a potential cofactor for HCV infection. Am J Public Health 92:670–676
Pineda JA, Rivero A, Rey C, Hernandez-Quero J, Vergara A, Munoz J, Aguado I, Santos J, Torronteras R, Gallardo JA (1995) Association between hepatitis C virus seroreactivity and HIV infection in non-intravenous drug abusing prostitutes. Eur J Clin Microbiol Infect Dis 14:460–464
Tortu S, Neaigus A, McMahon J, Hagen D (2001) Hepatitis C among noninjecting drug users: a report. Subst Use Misuse 36:523–534
Van Ameijden EJ, van den Hoek JA, Mientjes GH, Coutinho RA (1993) A longitudinal study on the incidence and transmission patterns of HIV, HBV and HCV infection among drug users in Amsterdam. Eur J Epidemiol 9:255–262
Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Brechot C, Brouwer JT, Chan SW, Chayama K, Chen DS (1994) A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 19:1321–1324
Enomoto N, Takada A, Nakao T, Date T (1990) There are two major types of hepatitis C virus in Japan. Biochem Biophys Res Commun 170:1021–1025
Simmonds P (1998) Variability of the hepatitis C genome. In: Reesink HW (ed) Hepatitis C virus. Karger, Basel
Pawlotsky JM, Tsakiris L, Roudot-Thoraval F, Pellet C, Stuyver L, Duval J, Dhumeaux D (1995) Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C. J Infect Dis 171:1607–1610
Kurbanov F, Tanaka Y, Sugauchi F, Kato H, Ruzibakiev R, Zalyalieva M, Yunusova Z, Mizokami M (2003) Hepatitis C virus molecular epidemiology in Uzbekistan. J Med Virol 69:367–375
Poynard T, Yuen MF, Ratziu V, Lai CL (2003) Viral hepatitis C. Lancet 362:2095–2100
Robaeys G, Van Vlierberghe H, Mathei C, Van Ranst M, Bruckers L, Buntinx F (2003) Compliance and effect of treatment for chronic hepatitis C (CHC) in intravenous drug users (IVDUs). J Hepatol 38:165
Stoove MA, Gifford SM, Dore GJ (2005) The impact of injecting drug use status on hepatitis C-related referral and treatment. Drug Alcohol Depend 77:81–86
Robaeys G, Mathei C, Buntinx F, Vanranst M (2002) Management of hepatitis C virus infections in intravenous drug users. Acta Gastroenterol Belg 65:99–100
Pybus OG, Charleston MA, Gupta S, Rambaut A, Holmes EC, Harvey PH (2001) The epidemic behavior of the hepatitis C virus. Science 292:2323–2325
Mathei C, Robaeys G, Van Damme P, Buntinx F, Verrando R (2005) Prevalence of hepatitis C in drug users in Flanders: determinants and geographic differences. Epidemiol Infect 133:127–136
Diamantis I, Bassetti S, Erb P, Ladewig D, Gyr K, Battegay M (1997) High prevalence and coinfection rate of hepatitis G and C infections in intravenous drug addicts. J Hepatol 26:794–797
Vitale F, Villafrate MR, Viviano E, Perna AM, Bonura F, Di Benedetto MA, Mazzola G, Colletti P, Prestileo T, Romano N (1998) Distribution of hepatitis C virus genotypes among intravenous drug users. A ten-year study in Palermo, Sicily. New Microbiol 21:335–342
Mathei C, Buntinx F, Van Damme P (2001) Is the prevalence of hepatitis C virus (HCV) RNA in anti-HCV-positive injection drug users positively correlated with age? J Infect Dis 184:659–660
Mathei C, Robaeys G, Van Ranst M, Van Damme P, Buntinx F (2005) The epidemiology of hepatitis C among injecting drug users in Belgium. Acta Gastroenterol Belg 68:50–54
Rodger AJ, Roberts S, Lanigan A, Bowden S, Brown T, Crofts N (2000) Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975. Hepatology 32:582–587
Harris KA, Gilham C, Mortimer PP, Teo CG (1999) The most prevalent hepatitis C virus genotypes in England and Wales are 3a and 1a. J Med Virol 58:127–131
Pohjanpelto P, Lappalainen M, Widell A, Asikainen K, Paunio M (1996) Hepatitis C genotypes in Finland determined by RFLP. Clin Diagn Virol 7:7–16
Bourliere M, Barberin JM, Rotily M, Guagliardo V, Portal I, Lecomte L, Benali S, Boustiere C, Perrier H, Jullien M, Lambot G, Loyer R, LeBars O, Daniel R, Khiri H, Halfon P (2002) Epidemiological changes in hepatitis C virus genotypes in France: evidence in intravenous drug users. J Viral Hepat 9:62–70
Elghouzzi MH, Bouchardeau F, Pillonel J, Boiret E, Tirtaine C, Barlet V, Moncharmont P, Maisonneuve P, du Puy-Montbrun MC, Lyon-Caen D, Courouce AM (2000) Hepatitis C virus: routes of infection and genotypes in a cohort of anti-HCV-positive French blood donors. Vox Sang 79:138–144
Stark K, Schreier E, Muller R, Wirth D, Driesel G, Bienzle U (1995) Prevalence and determinants of anti-HCV seropositivity and of HCV genotype among intravenous drug users in Berlin. Scand J Infect Dis 27:331–337
Berg T, Hopf U, Stark K, Baumgarten R, Lobeck H, Schreier E (1997) Distribution of hepatitis C virus genotypes in German patients with chronic hepatitis C: correlation with clinical and virological parameters. J Hepatol 26:484–491
Goeser T, Seipp S, Wahl R, Muller HM, Stremmel W, Theilmann L (1997) Clinical presentation of GB-C virus infection in drug abusers with chronic hepatitis C. J Hepatol 26:498–502
Ross RS, Viazov S, Renzing-Kohler K, Roggendorf M (2000) Changes in the epidemiology of hepatitis C infection in Germany: shift in the predominance of hepatitis C subtypes. J Med Virol 60:122–125
Driesel G, Wirth D, Stark K, Baumgarten R, Sucker U, Schreier E (1994) Hepatitis C virus (HCV) genotype distribution in German isolates: studies on the sequence variability in the E2 and NS5 region. Arch Virol 139:379–388
Dal Molin G, Ansaldi F, Biagi C, D’Agaro P, Comar M, Croce L, Tiribelli C, Campello C (2002) Changing molecular epidemiology of hepatitis C virus infection in northeast Italy. J Med Virol 68:352–356
Toniutto P, Falleti E, Gasparini V, Fabris C, Tisminetzky SG, Lombardelli T, Pacco P, Satta A, Pirisi M (1999) IgM antibody response to the hepatitis C virus core protein in intravenous drug users. Diagn Microbiol Infect Dis 33:69–73
Pirisi M, Toniutto P, Fabris C, Lombardelli T, Falleti E, Tisminetzky SG, Baralle F, Bartoli E (1998) Factors associated with serum HCV RNA positivity in anti-HCV antibody positive intravenous drug users. J Clin Epidemiol 51:423–427
Silini E, Bono F, Cividini A, Cerino A, Maccabruni A, Tinelli C, Bruno S, Bellobuono A, Mondelli M (1995) Molecular epidemiology of hepatitis C virus infection among intravenous drug users. J Hepatol 22:691–695
Saracco G, Sostegni R, Ghisetti V, Rocca G, Cariti G, Andreoni M, Tabone M, Roffi L, Calleri G, Ballare M, Minoli G, Sartori M, Tappero GF, Traverso A, Poggio A, Orani A, Maggi G, Rizzetto M (2000) Hepatitis C virus genotypes in a non-cirrhotic Italian population with chronic hepatitis C: correlation with clinical, virological and histological parameters. Results of a prospective multicentre study. J Viral Hepat 7:124–129
Cilla G, Garcia-Bengoechea M, Perez-Trallero E, Montalvo I, Vicente D, Arenas JI (1996) Genotyping of hepatitis C virus isolates from Basque Country, Spain. Epidemiol Infect 117:533–536
Bravo R, Soriano V, Garcia-Samaniego J, Gonzalez J, Castro A, Colmenero M, Carballo E, Mas A, Gonzalez-Lahoz J (1996) Prevalence of the genotypes of the hepatitis C virus in Spanish drug addicts with chronic hepatitis C. Spanish Group for the Study of Viral Hepatitis in HIV Positive Patients. Rev Clin Esp 196:673–677
Touceda S, Pereira M, Agulla A (2002) Prevalence of hepatitis C virus genotypes in the area of El Ferrol (La Coruna, Spain). Enferm Infecc Microbiol Clin 20:200–204
Westin J, Magnus L, Lagging L, Norkrans G, Wejstal R (1999) Chronic hepatitis C in Sweden: genotype distribution over time in different epidemiological settings. Scand J Infect Dis 31:355–358
Semprini AE, Persico T, Thiers V, Oneta M, Tuveri R, Serafini P, Boschini A, Giuntelli S, Pardi G, Brechot C (1998) Absence of hepatitis C virus and detection of hepatitis G virus/GB virus C RNA sequences in the semen of infected men. J Infect Dis 177:848–854
Farci P, Alter HJ, Govindarajan S, Wong DC, Engle R, Lesniewski RR, Mushahwar IK, Desai SM, Miller RH, Ogata N (1992) Lack of protective immunity against reinfection with hepatitis C virus. Science 258:135–140
Jarvis LM, Watson HG, McOmish F, Peutherer JF, Ludlam CA, Simmonds P (1994) Frequent reinfection and reactivation of hepatitis C virus genotypes in multitransfused hemophiliacs. J Infect Dis 170:1018–1022
Chan TM, Wu PC, Lau JY, Lai CL, Lok AS, Cheng IK (1994) Clinicopathologic features of hepatitis C virus infection in renal allograft recipients. Transplantation 58:996–1000
Prince AM, Brotman B, Huima T, Pascual D, Jaffery M, Inchauspe G (1992) Immunity in hepatitis C infection. J Infect Dis 165:438–443
Lai ME, Mazzoleni AP, Argiolu F, Devirgilis S, Balestrieri A, Purcell RH, Cao A, Farci P (1994) Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassemic children. Lancet 343:388–390
Herring BL, Page-Shafer K, Tobler LH, Delwart EL (2004) Frequent hepatitis C virus superinfection in injection drug users. J Infect Dis 190:1396–1403
Aitken C, McCaw R, Jardine D, Bowden S, Higgs P, Nguyen O, Crofts N, Hellard M (2004) Change in hepatitis C virus genotype in injecting drug users. J Med Virol 74:543–545
Hu YW, Balaskas E, Furione M, Yen PH, Kessler G, Scalia V, Chui L, Sher G (2000) Comparison and application of a novel genotyping method, semiautomated primer-specific and mispair extension analysis, and four other genotyping assays for detection of hepatitis C virus mixed-genotype infections. J Clin Microbiol 38:2807–2813
Kleter B, Brouwer JT, Nevens F, Van Doorn LJ, Elewaut A, Versieck J, Michielsen PP, Hautekeete ML, Chamuleau RA, Brenard R, Bourgeois N, Adler M, Quint WG, Bronkhorst CM, Heijtink RA, Hop WJ, Fevery J, Schalm SW (1998) Hepatitis C virus genotypes: epidemiological and clinical associations. Benelux Study Group on Treatment of Chronic Hepatitis C. Liver 18:32–38
Freeman AJ, Zekry A, Whybin LR, Harvey CE, van Beek IA, de Kantzow SL, Rawlinson WD, Boughton CR, Robertson PW, Marinos G, Lloyd AR (2000) Hepatitis C prevalence among Australian injecting drug users in the 1970s and profiles of virus genotypes in the 1970s and 1990s. Med J Aust 172:588–591
Hanbury R, Cohen M, Stimmel B (1977) Adequacy of sexual performance in men maintained on methadone. Am J Drug Alcohol Abuse 4:13–20
Koblin BA, Factor SH, Wu Y, Vlahov D (2003) Hepatitis C virus infection among noninjecting drug users in New York City. J Med Virol 70:387–390
Crofts N, Caruana S, Bowden S, Kerger M (2000) Minimising harm from hepatitis C virus needs better strategies. BMJ 321:899
Cattaneo C, Nuttall PA, Sokol RJ (1996) Detection of HIV, hepatitis B and hepatitis C markers in discarded syringes and bloodstains. Sci Justice 36:271–274
Thomas DL, Cannon RO, Shapiro CN, Hook EW III, Alter MJ, Quinn TC (1994) Hepatitis C, hepatitis B, and human immunodeficiency virus infections among non-intravenous drug-using patients attending clinics for sexually transmitted diseases. J Infect Dis 169:990–995
Haley RW, Fischer RP (2003) The tattooing paradox: are studies of acute hepatitis adequate to identify routes of transmission of subclinical hepatitis C infection? Arch Intern Med 163:1095–1098
Nishioka SA, Gyorkos TW (2001) Tattoos as risk factors for transfusion-transmitted diseases. Int J Infect Dis 5:27–34
Samuel MC, Doherty PM, Bulterys M, Jenison SA (2001) Association between heroin use, needle sharing and tattoos received in prison with hepatitis B and C positivity among street-recruited injecting drug users in New Mexico, USA. Epidemiol Infect 127:475–484
Beld M, Penning M, McMorrow M, Gorgels J, van den HA, Goudsmit J (1998) Different hepatitis C virus (HCV) RNA load profiles following seroconversion among injecting drug users without correlation with HCV genotype and serum alanine aminotransferase levels. J Clin Microbiol 36:872–877
Hahn JA, Page-Shafer K, Lum PJ, Ochoa K, Moss AR (2001) Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology 34:180–187
Acknowledgement
This work was financially supported by the Fonds voor Wetenschappelijk Onderzoek (FWO), grant code 1.5146.02N
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Matheï, C., Wollants, E., Verbeeck, J. et al. Molecular epidemiology of hepatitis C among drug users in Flanders, Belgium: association of genotype with clinical parameters and with sex- and drug-related risk behaviours. Eur J Clin Microbiol Infect Dis 24, 514–522 (2005). https://doi.org/10.1007/s10096-005-1376-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10096-005-1376-9